Worldwide adult obesity has more than doubled since 1990
Treatment adherence According to a large RWS enrolling 26,522 individuals, new users of liraglutide 3.0 mg exhibited the highest persistence rate compared to patents on other AOM such as naltrexone/bupropion, lorcaserin, and phentermine/topiramate extended release 109
Lawsuits allege that patients who took these peptides suffered severe health issues, including gastrointestinal injuries and other complications
GLP-1 receptor (GLP-1R) agonists control glycemia via glucose-dependent mechanisms of action and promote weight loss in obese and diabetic individuals
Retatrutide creates the perfect environment for fat loss through appetite suppression, improved insulin sensitivity, and increased energy expenditure
We report a DKA rate at 5 years of 2.1%